Massachusetts-based Radius Health moving into Philadelphia with 100 jobs
WALTHAM, Mass. – Radius Health (RDUS), which is developing therapies for patients with osteoporosis and other serious diseases, opened a 14,000 square-foot site in Pennsylvania and employ 100 there, the Philadelphia Business Journal reported recently. Check for Radius Health jobs here.
The new site will be the home of Radius Health’s pharmacovigilance and medical affairs teams. The expansion into Pennsylvania comes as the company is preparing to launch its first commercial product, the Journal said. In May, the U.S. Food and Drug Administration accepted Radius Health’s New Drug Application for abaloparatide-sc, an investigational synthetic peptide for the potential treatment of postmenopausal women with osteoporosis. Last year Radius submitted a Centralized Marketing Authorization Application for abaloparatide-SC in the European Union. The company said it anticipates a regulatory ruling in Europe later this year. Radius delayed filing its NDA with the FDA until March of this year, instead of at the same time as the CMA in the EU. The company said rushing the NDA had a potential to create unnecessary risk.
Expansion has been part of Radius’ plan for some time. Last year the company told BioSpace Radius is in “high growth mode” and expected the company to double in size. During the previous year, Radius grew its employee base from 25 employees to 73. And they’re not done. Ward told the Journal he anticipates Radius will continue to grow this year to about 300 employees in order to be ready for commercial approval of abaloparatide-SC.
READ MORE of this story at BioSpace by Alex Keown. Photo courtesy of Radius Health.